Joseph C. Cappelleri earned his MS in statistics from the City University of New York (Baruch College), PhD in psychometrics from Cornell University, and MPH in epidemiology from Harvard University. Dr. Cappelleri is an executive director of biostatistics in the Statistical Research and Data Science Center, and head of its Health Economics and Outcomes Research Statistics Group, at Pfizer Inc. As an adjunct professor, he has served on the faculties at Brown University (biostatistics), Tufts Medical Center (medicine), and the University of Connecticut (statistics). The most published author in the history of Pfizer, and among the most prolific researchers in the pharmaceutical industry, he has co-authored approximately 1,300 external presentations and 650 publications on clinical and methodological topics, including on regression-discontinuity designs, meta-analysis, and health measurement scales. Dr. Cappelleri is the lead author of the book “Patient-Reported Outcomes: Measurement, Implementation and Interpretation” and has co-authored or co-edits four other books. He is an elected recipient of the Craig A. Saxton Clinical Development Excellence Award at Pfizer, recipient of the ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Award, and fellow of the American Statistical Association.
Dr. Dooti Roy is a people leader, a global product owner and a methodology statistician who enjoys developing/deploying innovative clinical research and statistical visualization tools with expertise in creating and leading dynamic cross-functional collaborations to efficiently solve complex problems. At Boehringer Ingelheim, she is currently focused on research and methodological applications of Bayesian statistics, artificial intelligence and machine learning on clinical efficacy analyses, patient adherence, and dose-finding. She is the co-creator of UConn Summer Academy, the SIP conference and is an adjunct faculty at UConn Statistics. She is passionate about promoting diversity and inclusion, mentoring, cross-cultural collaborations, and leadership development.
Naitee Ting is a Fellow of American Statistical Association (ASA). He is currently a Director in the Department of Biostatistics and Data Sciences at Boehringer-Ingelheim Pharmaceuticals Inc. (BI). He joined BI in September of 2009, and before joining BI, he was at Pfizer Inc. for 22 years (1987-2009). Naitee received his Ph.D. in 1987 from Colorado State University (major in Statistics). He has an M.S. degree from Mississippi State University (1979, Statistics) and a B.S. degree from College of Chinese Culture (1976, Forestry) at Taipei, Taiwan. Naitee published articles in Technometrics, Statistics in Medicine, Drug Information Journal, Journal of Statistical Planning and Inference, Journal of Biopharmaceutical Statistics, Biometrical Journal, Statistics and Probability Letters, and Journal of Statistical Computation and Simulation. His book “Dose Finding in Drug Development” was published in 2006 by Springer, and is considered as the leading reference in the field of dose response clinical trials. The book “Fundamental Concepts for New Clinical Trialists”, co-authored with Scott Evans, was published by CRC in 2015. Another book “Phase Ⅱ Clinical Development of New Drugs”, co-authored with Chen, Ho, and Cappelleri was published in 2017 (Springer). Naitee is an adjunct professor of Columbia University, University of Connecticut, and Colorado State University. Naitee has been an active member of both the ASA and the International Chinese Statistical Association (ICSA).
Dr. Yaohua Zhang is an Associate Director at Vertex Pharmaceuticals. Since joining Vertex in 2017, Yaohua has worked on various trials from phase Ⅰ to phase Ⅲ and submission work. Most recently, he is the project lead statistician of two disease areas and is actively in strategic planning, validating endpoints and theoretical research. Yaohua graduated with a PhD degree in statistics from UConn in 2017 and since then has been an active alumnus. He has been actively volunteering in NESS activities and sit on several NESS committees. Apart from his daily busy work, he also conducts several research topics related to practical issues seen in the setting of pharmaceutical industry through collaboration with colleagues or interns.
